Not sure how that works when there are fierce competitions, and openai's product is not substantially better than the rest. There are US competitors, then China.

Take ozempic as an example. The word is already part of the culture, but the company is losing badly to lly. Novo nordisk is projecting revenue DECLINE while eli lilly is still growing massively. I am not even sure people know other glp1 drugs other than ozempic. I don't even remember lilly drugs name.

I think people should not underestimate the market. It's a dynamic game where engineering intuition might not be enough